Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Cancer Science|August 4, 2010
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccinationKanako Iseki, Hiromi Matsunaga, Nobukazu Komatsu, et al.
Cancer Science|September 3, 2015
Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccineSatoko Matsueda, Shigeki Shichijo, Sayaka Nagata, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2009
An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 allelesYasunobu Terasaki, Shigeki Shichijo, Yamei Niu, et al.
The Prostate|June 4, 2004
A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patientsSatoko Matsueda, Akihisa Yao, Yuki Ishihara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype allelesSatoko Matsueda, Hiroko Takedatsu, Akihisa Yao, et al.
Plos One|November 10, 2009
An association analysis between mitochondrial DNA A10398G polymorphism and temperament in Japanese young adultsKunihiro Kishida, Mihoko Tominaga, Kiminori Matsubara, et al.
The Prostate|July 30, 2003
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccinationMasanori Noguchi, Kazuhiko Kobayashi, Norie Suetsugu, et al.
Cancer Immunology, Immunotherapy : CII|August 29, 2006
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype allelesTakafumi Minami, Satoko Matsueda, Hiroko Takedatsu, et al.
The Kurume Medical Journal|April 26, 2012
Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a caseKousuke Ueda, Masanori Noguchi, Sigetaka Suekane, et al.
Cancer Immunology, Immunotherapy : CII|January 6, 2016
A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancerMasanori Noguchi, Fukuko Moriya, Noriko Koga, et al.
Pageof 10